The Pharmacological Profile of (-)Deprenyl (Selegiline) and its Relevance for Humans: A Personal View (Q36223329)

12 August 2017

1 reference

title

The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view (English)

1 reference

12 August 2017

The Pharmacological Profile of (-)Deprenyl (Selegiline) and its Relevance for Humans: A Personal View (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

14 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

14 October 2022

author name string

J. Knoll

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1608919

14 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1608919

14 October 2022

publication date

1 May 1992

1 reference

full work available at URL

12 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0773.1992.tb00480.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0773.1992.tb00480.x/fullpdf

14 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Basic and Clinical Pharmacology and Toxicology

14 October 2022

published in

1 reference

12 August 2017

volume

70

1 reference

12 August 2017

issue

5 Pt 1

1 reference

12 August 2017

page(s)

317-321

1 reference

L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00480.X

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS

14 October 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation

14 October 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

14 October 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Apomorphine, deprenyl, and yohimbine fail to increase sexual behavior in rhesus males

14 October 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Parkinson's disease: management

14 October 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys

14 October 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?

14 October 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

14 October 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The use of selegiline in Alzheimer's patients with behavior problems.

14 October 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Quantitative localization of human brain monoamine oxidase B by large section autoradiography using L-[3H]deprenyl

14 October 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

14 October 2022

19

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

On the dual nature of monoamine oxidase

14 October 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence

14 October 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The pharmacology of (-)deprenyl

14 October 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

14 October 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The pharmacology of selegiline ((-)deprenyl). New aspects

14 October 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Some puzzling pharmacological effects of monoamine oxidase inhibitors

14 October 2022

36

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Long-lasting, true aphrodisiac effect of (-)-deprenyl in sexually sluggish old male rats

14 October 2022

39

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl

14 October 2022

40

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

(−)Deprenyl and (−)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin

14 October 2022

41

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

14 October 2022

42

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Brief information on an early phase-II study with deprenyl in demented patients.

14 October 2022

44

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Maintenance on L-deprenyl prolongs life in aged male rats

14 October 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Effect of deprenyl on the progression of disability in early Parkinson's disease

14 October 2022

46

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

14 October 2022

47

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis

14 October 2022

48

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Absence of "cheese effect" during deprenyl therapy: some recent studies.

14 October 2022

49

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine

14 October 2022

50

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

Cognitive effects of L-deprenyl in Alzheimer's disease.

14 October 2022

52

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

14 October 2022

54

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

A procedure for measuring neuromelanin in neurocytes by a TV-image analyser

14 October 2022

55

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00480.X

14 October 2022

Identifiers

1 reference

release_kvy7kixq5zcpxlroypxltisldy

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kvy7kixq5zcpxlroypxltisldy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference